Clinical & Experimental Metastasis

, Volume 22, Issue 7, pp 575–586 | Cite as

Pre-clinical Study of 213Bi Labeled PAI2 for the Control of Micrometastatic Pancreatic Cancer

  • Chang F. Qu
  • Emma Y. Song
  • Yong Li
  • Syed M. A. Rizvi
  • Chand Raja
  • Ross Smith
  • Alfred Morgenstern
  • C. Apostolidis
  • Barry J. Allen
Article

Abstract

Purpose: The urokinase plasminogen activator (uPA) and its receptor (uPAR) are expressed by pancreatic cancer cells and can be targeted by the plasminogen activator inhibitor type 2 (PAI2). We have labeled PAI2 with 213Bi to form the alpha conjugate (AC), and have studied its in vitro cytotoxicity and in vivo efficacy.

Methods and Materials: The expression of uPA/uPAR on pancreatic cell lines, human pancreatic cancer tissues, lymph node metastases, and mouse xenografts were detected by immunohistochemistry, confocal microscopy, and flow cytometry. Cytotoxicity was assessed by the MTS and TUNEL assay. At 2 days post-cancer cell subcutaneous inoculation, mice were injected with AC by local or systemic injection.

Results: uPA/uPAR is strongly expressed on pancreatic cancer cell lines and cancer tissues. The AC can target and kill cancer cells in vitro in a concentration-dependent fashion. Some 90% of TUNEL positive cells were found after incubation with 1.2 MBq/ml of AC. A single local injection of ~222 MBq/kg 2 days post-cell inoculation can completely inhibit tumor growth over 12 weeks, and an intraperitoneal injection of 111 MBq/kg causes significant tumor growth delay.

Conclusions:213Bi-PAI2 can specifically target pancreatic cancer cells in vitro and inhibit tumor growth in vivo. 213Bi-PAI2 may be a useful agent for the treatment of post-surgical pancreatic cancer patients with minimum residual disease.

Keywords

alpha particles pancreatic cancer plasminogen activator inhibitor type 2 radioimmunotherapy urokinase plasminogen activator 

References

  1. 1.
    Sener, SF, Fremgen, A, Menck, HR,  et al. 1999Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985–1995, using the National Cancer DatabaseJ Am Coll Surgeons18917Google Scholar
  2. 2.
    Yamamoto, M, Ohashi, O, Saitoh, Y 1998Japan Pancreatic Cancer Registry: current statusPancreas1623842CrossRefPubMedGoogle Scholar
  3. 3.
    Conlon, KC, Klimstra, DS, Brennan, MF 1996Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivorsAnn Surg223273279PubMedGoogle Scholar
  4. 4.
    Goldenberg, DM 2002Targeted therapy of cancer with radiolabeled antibodiesJ Nucl Med43693713PubMedGoogle Scholar
  5. 5.
    Behr, TM, Wormann, B, Gramatzki, M,  et al. 1999Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignanciesClin Cancer Res53304s14sPubMedGoogle Scholar
  6. 6.
    Goldenberg, DM 2001The role of radiolabeled antibodies in the treatment of non-Hodgkin’s lymphoma: the coming of age of radioimmunotherapyCrit Rev Oncol Hematol39195201PubMedGoogle Scholar
  7. 7.
    Gold, DV, Modrak, DE, Schutsky, K,  et al. 2004Combined 90Yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograftInt J Cancer10961826CrossRefPubMedGoogle Scholar
  8. 8.
    Kaminski, MS, Estes, J, Zasadny, KR,  et al. 2000Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experienceBlood96125966PubMedGoogle Scholar
  9. 9.
    McDevitt, MR, Sgouros, G, Finn, RD,  et al. 1998Radioimmunotherapy with alpha-emitting nuclidesEur J Nucl Med25134151CrossRefPubMedGoogle Scholar
  10. 10.
    Allen, BJ 1999Can alpha-immunotherapy succeed where other systemic modalities have failedNucl Med Commun202057PubMedGoogle Scholar
  11. 11.
    Kennel, SJ, Boll, R, Stabin, M,  et al. 1999Radioimmunotherapy of micrometastases in lung with vascular targeted 213BiBr J Cancer8017584PubMedGoogle Scholar
  12. 12.
    Allen, B, Blagojevic, N 1997Alpha and beta emitting radiolanthanides in targeted cancer therapyNucl Med Commun202057Google Scholar
  13. 13.
    Li, Y, Rizvi, SM, Ranson, M,  et al. 2002213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal modelBr J Cancer861197203CrossRefPubMedGoogle Scholar
  14. 14.
    Ballangrud, AM, Yang, WH, Palm, S,  et al. 2004Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expressionClin Cancer Res10448997PubMedGoogle Scholar
  15. 15.
    Seidl, C, Schrock, H, Seidenschwang, S,  et al. 2005Cell death triggered by alpha-emitting 213Bi-immunoconjugates in HSC45-M2 gastric cancer cells is different from apoptotic cell deathEur J Nucl Med Mol Imag3227485Google Scholar
  16. 16.
    Beyer, GJ, Miederer, M, Vranjes-Duric, S,  et al. 2004Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using 149Tb-rituximabEur J Nucl Med Mol Imag3154754Google Scholar
  17. 17.
    Jurcic, JG, Larson, SM, Sgouros, G,  et al. 2002Targeted alpha particle immunotherapy for myeloid leukemiaBlood10012339PubMedGoogle Scholar
  18. 18.
    Schmitt, M, Wilhelm, OG, Reuning, U,  et al. 2000The urokinase plasminogen activation system as a novel target for tumour therapyFibrinol Proteol1411432CrossRefGoogle Scholar
  19. 19.
    Pollanen, J, Stephens, RW, Vaheri, A 1991Directed plasminogen activation at the surface of normal and malignant cellsAdv Cancer Res57273328PubMedGoogle Scholar
  20. 20.
    Andreasen, PA, Egelund, R, Petersen, HH 2000The plasminogen activation system in tumor growth, invasion, and metastasisCell Mol Life Sci572540PubMedGoogle Scholar
  21. 21.
    Mueller, BM, Yu, YB, Laug, WE 1995Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid/scid miceProc Nat Acad Sci U.S.A.922059Google Scholar
  22. 22.
    Marutsuka, K, Hasui, Y, Asada, Y,  et al. 1995Effects of suramin on metastatic ability, proliferation, and production of urokinase-type plasminogen activator and plasminogen activator inhibitor type 2 in human renal cell carcinoma cell line SN12C-PM6Clin Exp Metastasis1311622CrossRefPubMedGoogle Scholar
  23. 23.
    Kruithof, EK, Baker, MS, Bunn, CL 1995Biological and clinical aspects of plasminogen activator inhibitor type 2Blood86400724PubMedGoogle Scholar
  24. 24.
    Baker, MS, Bleakley, P, Woodrow, GC,  et al. 1990Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradationCanc Res50467684Google Scholar
  25. 25.
    Al-Ejeh, F, Croucher, D, Ranson, M 2004Kinetic analysis of plasminogen activator inhibitor type-2: urokinase complex formation and subsequent internalisation by carcinoma cell linesExp Cell Res29725971PubMedGoogle Scholar
  26. 26.
    Apostolidis, C, Carlos-Marquez, R, Janssens, W,  et al. 2001Cancer treatment using Bi-213 and Ac-225 in radioimmunotherapyNucl News442933Google Scholar
  27. 27.
    Ranson, M, Tian, Z, Andronicos, NM,  et al. 2002In vitro cytotoxicity of bismuth-213 (213Bi)-labeled-plasminogen activator inhibitor type 2 (alpha-PAI-2) on human breast cancer cellsBreast Cancer Res Treat7114959CrossRefPubMedGoogle Scholar
  28. 28.
    Gavrieli, Y, Sherman, Y, Ben-Sasson, SA 1992Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentationJ Cell Biol119493501CrossRefPubMedGoogle Scholar
  29. 29.
    Gleave, M, Hsieh, JT, Gao, CA,  et al. 1991Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblastsCancer Res51375361PubMedGoogle Scholar
  30. 30.
    Allen, BJ, Tian, Z, Rizvi, SM,  et al. 2003Preclinical studies of targeted alpha therapy for breast cancer using 213Bi-labelled-plasminogen activator inhibitor type 2Br J Cancer8894450CrossRefPubMedGoogle Scholar
  31. 31.
    Wang, W, Abbruzzese, JL, Evans, D,  et al. 1999Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelAOncogene18455463PubMedGoogle Scholar
  32. 32.
    Cantero, D, Friess, H, Deflorin, J,  et al. 1997Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinomaBr J Cancer7538895PubMedGoogle Scholar
  33. 33.
    Takeuchi, Y, Nakao, A, Harada, A,  et al. 1993Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical studyAm J Gastroenterol88192833PubMedGoogle Scholar
  34. 34.
    Macklis, RM, Lin, JY, Beresford, B,  et al. 1992Cellular kinetics, dosimetry, and radiobiology of alpha-particle radioimmunotherapy: induction of apoptosisRadiation Research1302206PubMedGoogle Scholar
  35. 35.
    Al-Ejeh, F, Croucher, D, Ranson, M 2004Kinetic analysis of plasminogen activator inhibitor type-2: urokinase complex formation and subsequent internalsiation by carcinoma cell lines.Exp Cell Res29725971PubMedGoogle Scholar
  36. 36.
    Harms-Ringdahl, M, Nicotera, P, Radford, IR 1996Radiation induced apoptosisMutat Res3661719PubMedGoogle Scholar
  37. 37.
    Ward, JF 1994The complexity of DNA damage: relevance to biological consequencesInt J Radiat Biol6642732PubMedGoogle Scholar
  38. 38.
    Friedberg, Errol C, Walker, Graham C, Siede, W 1995DNA Repair and MutagenesisASM PressWashington D.CGoogle Scholar
  39. 39.
    Allen, BJ, Raja, C, Rizvi, SMA,  et al. 2004Targeted alpha therapy for cancerPhys Med Biol49370312PubMedGoogle Scholar

Copyright information

© Springer 2006

Authors and Affiliations

  • Chang F. Qu
    • 1
    • 2
  • Emma Y. Song
    • 1
    • 2
  • Yong Li
    • 1
  • Syed M. A. Rizvi
    • 1
  • Chand Raja
    • 1
  • Ross Smith
    • 3
    • 4
  • Alfred Morgenstern
    • 5
  • C. Apostolidis
    • 5
  • Barry J. Allen
    • 1
    • 2
    • 6
  1. 1.Centre for Experimental Radiation Oncology, Cancer Care CentreSt George HospitalKogarahAustralia
  2. 2.University of New South WalesAustralia
  3. 3.Department of SurgeryRoyal North Shore HospitalAustralia
  4. 4.University of SydneyAustralia
  5. 5.European Commission, Joint Research CentreInstitute for Transuranium ElementsKarlsruheGermany
  6. 6.Centre for Experimental Radiation Oncology, Cancer Care CentreSt George HospitalKogarahAustralia

Personalised recommendations